H Yki-Jarvinen - New England Journal of Medicine, 2004 - content.nejm.org Insulin resistance both precedes and predicts type 2 diabetes mellitus. 1
Although exercise and weight loss ameliorate insulin resistance and may in some
cases prevent or delay onset of the disease, 2 therapy that combats insulin ... Cited by 838 - Related articles - BL Direct - All 6 versions
- ►endojournals.org JL Evans, ID Goldfine, BA Maddux, GM … - Endocrine Reviews, 2002 - Endocrine Soc In both type 1 and type 2 diabetes, the late diabetic complications in nerve,
vascular endothelium, and kidney arise from chronic elevations of glucose and
possibly other metabolites including free fatty acids (FFA). Recent ... Cited by 593 - Related articles - BL Direct - All 18 versions
- ►endojournals.org H Bays, L Mandarino, RA DeFronzo - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in liver
and muscle and impaired insulin secretion. Considerable evidence also implicates
deranged adipocyte metabolism and altered fat topography in the ... Cited by 245 - Related articles - All 4 versions
- ►cell.com P Arner - Trends in Endocrinology & Metabolism, 2003 - Elsevier Globally, the prevalence of obesity is escalating, and insulin resistance
resulting from increased (predominantly visceral) adipose tissue mass has been
identified as a key factor that could drive parallel rises in type 2 ... Cited by 234 - Related articles - All 11 versions
- ►ahajournals.org MR Langenfeld, T Forst, C Hohberg, P Kann, G … - Circulation, 2005 - Am Heart Assoc Methods and Results— We compared the effects of pioglitazone-based therapy (45
mg/d) and glimepiride-based treatment (2.7±1.6 mg/d) for 12 and 24 weeks on
metabolic control (HbA 1c ), insulin resistance (homeostasis model ... Cited by 186 - Related articles - All 14 versions
- ►ahajournals.org JPH van Wijk, EJP de Koning, EP Martens, TJ … - Arteriosclerosis, thrombosis, and vascular biology, 2003 - Am Heart Assoc We evaluated study population characteristics and treatment effects on blood
lipids between studies in which either rosiglitazone (RSG) or pioglitazone (PIO)
was investigated in patients with type 2 diabetes. We performed a summary ... Cited by 131 - Related articles - BL Direct - All 7 versions
- ►endojournals.org Y Miyazaki, A Mahankali, E Wajcberg, M … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc We examined the effect of pioglitazone (PIO) on circulating adipocytokine levels
to elucidate the mechanisms by which thiazolidinediones improve insulin
resistance in type 2 diabetes mellitus (T2DM). Twenty-three subjects with ... Cited by 115 - Related articles - BL Direct - All 5 versions
- Free from Publisher B Charbonnel, J Dormandy, E Erdmann, M … - Diabetes Care, 2004 - ncbi.nlm.nih.gov OBJECTIVE: The PROspective pioglitAzone Clinical Trial In macroVascular Events
(PROactive) assesses the effect of pioglitazone, a peroxisome
proliferator-activated receptor agonist, with anti-inflammatory and ... Cited by 110 - Related articles - BL Direct - All 3 versions
TM Larsen, S Toubro, A Astrup - International journal of obesity, 2003 - nature.com The nuclear hormone receptor peroxisome proliferator-activated receptor gamma
(PPAR ) is a member of the PPAR family. The endogenous activators of all members
of the PPAR family are a variety of fatty acids, which suggests that the ... Cited by 106 - Related articles - BL Direct - All 5 versions
